|  |  |  |  |  |
| Company | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation |
| Item | GUCA1A Human Pre-designed siRNA Set A | Amyloid β-Protein Fragment 25-35 | Glukagon (19-29) (human),TFA | Heme Oxygenase-1-IN-1 | Recombinant Mouse CXCL1/KC Protein |
| Catalog Number | G1470770 | A107853 | G321154 | H654942 | rp168795 |
| Price | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |
| Quantity | 1Set | 100mg, 5mg, 2mg, 1mg, 25mg | 250mg, 5mg, 50mg, 10mg, 25mg | 1ml | 100µg, 10µg, 50µg, 1mg |
| Type | Bioactive Small Molecules | Chelating Agents & Ligands | Chelating Agents & Ligands | Chelating Agents & Ligands | Chelating Agents & Ligands |
| Description | GUCA1A Human Pre-designed siRNA Set A contains three designed siRNAs for GUCA1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components GUCA1A siRNA-1: 5 nmol (HPLC) GUCA1A siRNA-2: 5 nmol (HPLC) GUCA1A siRNA-3: 5 nmol (HPLC) siRNA Negative GUCA1A Human Pre-designed siRNA Set A contains three designed siRNAs for GUCA1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components GUCA1A siRNA-1: 5 nmol (HPLC) GUCA1A siRNA-2: 5 nmol (HPLC) GUCA1A siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40) peptides. It has a β-sheet and β-turn structure. Amino Acid Sequence Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetFunctional domain of Aβ required for both neurotrophic and neurotoxic effects... Read More | Inquire | Heme Oxygenase-1-IN-1 (Compound 2) is a heme oxygenase 1 ( HO-1 ) inhibitor with an IC 50 of 0.25 µMIC50& Target:IC 50 : 0.25 µM (HO-1) | Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationFunction N-terminal glycine. Full-length mature chain lacking the signal peptideFunctionHas chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationFunction N-terminal glycine. Full-length mature chain lacking the signal peptideFunctionHas chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity.Post-translationalN-terminal processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) are produced by proteolytic cleavage after secretion from peripheral blood monocytes... Read More |
| Get Quote | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |